Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria

This publication has 68 references indexed in Scilit:

• Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species
  Antimicrobial Agents and Chemotherapy, 2009
• Does One Voriconazole Breakpoint Suit All Candida Species?
  Journal of Clinical Microbiology, 2007
• Candida glabrata Fungemia in Transplant Patients Receiving Voriconazole after Fluconazole
  Transplantation, 2005
• Emerging azole antifungals
  Expert Opinion on Emerging Drugs, 2005
• Rapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole
  Antimicrobial Agents and Chemotherapy, 2005
• Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles
  Antimicrobial Agents and Chemotherapy, 2004
• In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model
  Antimicrobial Agents and Chemotherapy, 2003
• Comparison of Visual and Spectrophotometric Methods of Broth Microdilution MIC End Point Determination and Evaluation of a Sterol Quantitation Method for In Vitro Susceptibility Testing of Fluconazole and Itraconazole against Trailing and Nontrailing Candida Isolates
  Antimicrobial Agents and Chemotherapy, 2002
• A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients
  Clinical Infectious Diseases, 2001
• Voriconazole: A second-generation triazole
  Drugs of Today, 2001